Podium to Practice: ESMO® 2025 – GU: KEYNOTE-905

Podium to Practice: ESMO® 2025 – GU: KEYNOTE-905

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christian Kollmannsberger

Icon Chair Speaker

Speakers

Dr. Sebastien Hotte

Dr. Maria Jiang

Studies / Trials Discussed

LBA2 – Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study

Studies/trials discussed:

LBA2 – Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study
Tagged